Janssen Vaccines

Janssen Vaccines, a subsidiary of Johnson & Johnson, is a leading biotechnology company focused on the development and manufacturing of vaccines for infectious diseases. Headquartered in Leiden, Netherlands, the company utilizes its proprietary AdVac viral vector technology and PER.C6 cell line to create innovative preventative treatments. Its portfolio includes the widely deployed single-dose COVID-19 vaccine and a multi-stage Ebola vaccine regimen. Janssen Vaccines continues to research solutions for high-burden diseases such as extra-intestinal pathogenic E. coli and Zika virus. The company operates as a core component of Johnson & Johnson's Innovative Medicine division, collaborating with global health organizations to ensure broad access to its products. While recently streamlining its focus, the entity remains a critical driver of viral vector innovation in the pharmaceutical industry.